# VivaHeart.AI (PRD)

Author: Carmen Pena Contributors: N/A

## **Table of Contents**

/ivaHe	eart.AI (PRD)	. 1
Rel	evant Documents	. 3
1.	About	. 3
2.	Market Insights	. 3
•	Competitor and Market Analysis	. 4
•	Technology Analysis	. 1
•	Customer Segments	. 1
•	User Personas	. 1
3.	The Problem	. 3
•	Use Cases	. 3
•	Pain Points	. 4
•	Problem Statement	. 4
•	Hypotheses and Mission Statement	. 5
4.	The Solution	. 5
•	Ideation	. 5
•	Leveraging AI	. 6
•	Feature Prioritization	. 7
•	AI MVP	. 7
•	Roadmap	. 8
•	Technical Architecture	11
•	Assumptions and Constraints	12
	Risks	13
5.	Requirements	14
•	Functional Requirements	15
•	Non-functional Requirements	17
•	Al & Data Requirements	19
6.	Challenges	22
7.	Positioning	24
8.	Measuring Success	25
	Metrics	25

## <u>Carmen Pena</u> - VivaHeart.Al

## Al Product Requirements Doc (PRD)

•	•	Al-specific Metrics	. 25
•	•	What is your North Star Metric?	. 26
9.		Launching	. 27
•	•	Stakeholders & Communication	. 27
	•	Roll-out strategy	. 28

## **Relevant Documents**

## 1. About

Heart disease remains the leading cause of death worldwide, with women and smokers being particularly vulnerable. Women smokers are at a higher risk of developing coronary artery disease, yet detection in this group is often delayed.

Cardiac CT scans provide early insights, but current diagnostic tools miss early signs, like subtle inflammation in coronary arteries. Leveraging AI for CT scan analysis offers a powerful opportunity to detect heart disease in female smokers early and improve outcomes.

## 2. Market Insights

The countries with the highest populations of female smokers are:

- 1. **Serbia** 34% of women are smokers.
- 2. **Greece** 27% of women are smokers.
- 3. **Bulgaria** 26% of women are smokers.
- 4. **France** 25% of women are smokers.
- 5. **Germany** 23% of women are smokers.
- 6. **Hungary** 22% of women are smokers.
- 7. **Russia** 21% of women are smokers.
- 8. **Spain** 20% of women are smokers.
- 9. **Turkey** 18% of women are smokers.
- 10. China 3% of women are smokers.

These countries represent the highest percentages of female smokers, highlighting significant populations at risk of heart-related health issues.

VivaHeart.AI addresses a critical gap in the healthcare AI landscape by focusing on early heart disease detection in female smokers, a high-risk group often underserved by traditional diagnostic tools. While many competitors in the AI cardiac diagnostics space provide general solutions, few specifically target gender-specific risks and the subtle signs of coronary artery disease in women smokers. This creates a significant opportunity for VivaHeart.AI to fulfill an unmet need and potentially lead this niche market, leveraging AI-powered CT scan analysis for better outcomes in this vulnerable population.

Cardiovascular diagnostics is a growing market, expected to reach \$32.1 billion by 2028. Al in medical imaging is predicted to grow due to its ability to improve accuracy and reduce diagnostic time. Women's health and precision medicine are gaining traction as key healthcare segments. Addressing gender-specific diseases with AI could fill a market gap.

## • Competitor and Market Analysis

#### Leaders

**GE Healthcare** is a global leader in medical imaging and diagnostics, and their incorporation of AI in cardiac diagnostics, including CT scan analysis, is robust. Their wide range of offerings across various healthcare domains, strong R&D investment, and partnerships make them a leader in this space.

Market share: 25-30%

**Siemens Healthineers** is also a major leader in the medical imaging industry, with strong capabilities in Al integration, particularly for heart disease diagnosis. Their Al-driven systems are used across a wide range of cardiac conditions, making them a top player.

Market share: 20-25%

#### High Performers

**HeartFlow's** focus on AI-driven analysis for coronary artery disease (CAD), using CT scans, positions them as a high performer. Their non-invasive approach is cutting-edge, and their products are gaining traction in hospitals for personalized care.

Market share: 10-15%

**Arterys** has a strong focus on AI-powered medical imaging, particularly in cardiology. Their solutions offer real-time cloud-based analysis, which is gaining popularity among healthcare providers for its efficiency and precision in detecting heart disease. Arterys provides customizable AI models that can adapt to different hospital settings and integrate into various workflows, particularly for cardiac imaging. Market share: 5-10%

#### Contenders

**Zebra Medical Vision** provides AI-based tools for radiology, including heart disease detection, but their approach is more generalized, and they have not focused on specific vulnerable populations like female smokers. They are a strong contender due to their AI prowess but lack the niche focus.

Market share: 5-7%

#### Niche

**VivaHeart.AI** falls into the **niche player** category as it focuses specifically on early detection of heart disease in female smokers, an underserved market. With the right approach, VivaHeart.AI could fill a critical gap that larger players aren't addressing. However, it is still emerging compared to more established solutions.

Competitor and Market Analysis					
Leaders	High Performers				
GE HealthCare  Market share: 25-30%  SIEMENS Healthineers  Market share: 20-25%	Heart Flow  Market share: 10-15%  ARTERYS  Medical Imaging Cloud AI  Market share: 5-10%				
Contenders	Niche				
Zebra medical vision  Market share: 5-7%	VivaHeart.AI (New)				

## Technology Analysis

Competitor	Deep Learning & Neural Networks	ASR Automatic Speech Recognition	NLP Natural Language Processing	Speech Synthesis /Enhancement	Real-Time Processing	Emotion /Sentiment Analysis	Customizable/Adaptive Models
GE Healthcare	Yes	No	Limited in cardiac tools	No	Yes	No	Limited to workflows
Siemens Healthineers	Yes	No	Limited in cardiac tools	No	Yes	No	Limited to workflows
HeartFlow	Yes	No	No	No	Yes	No	Yes(patient-specific)
Artery's	Yes	No	Limited in medical reports	No	Yes	No	Yes(hospital-workflows)
Zebra Medical Vision	Yes	No	No	No	Yes	No	No

**GE Healthcare's Edison Al Platform** uses **Al-powered imaging** to improve the detection of heart conditions, helping doctors identify issues more quickly and accurately. GE Healthcare leverages deep learning and neural networks in their **Edison Al platform** for image reconstruction, enhancement, and diagnostic assistance. Uses real-time Al for **cardiac imaging analysis**, allowing for faster diagnosis by processing scans quickly. GE's Al models can be adapted based on specific hospital needs, but customization in cardiac diagnostics is more limited to imaging workflows rather than patient-specific models.

**Siemens Healthineers** leverages its **Al-Rad Companion**, a suite of Al-powered imaging software designed to assist radiologists. For cardiology, the platform helps analyze CT and MRI scans to detect abnormalities in the heart. Deep learning and neural networks are used in Siemens' **Al-Rad Companion** to enhance image quality, automate diagnostic measurements, and identify cardiac issues. Uses **real-time Al** to improve workflow efficiency in cardiac diagnostics, such as fast image analysis and reporting. Some customization in terms of workflow integration, but their deep learning models are standardized for cardiac image analysis.

**HeartFlow** uses AI to create personalized, non-invasive 3D models of coronary arteries from cardiac CT scans. Their HeartFlow Analysis uses deep learning algorithms to simulate blood flow and detect blockages or areas of reduced blood flow. Deep learning models are central to HeartFlow's technology, especially in generating 3D models and simulating blood flow to detect coronary artery disease. involves real-time AI-driven analysis of CT scan data to create 3D models of coronary arteries. Heart Flow's models are largely customizable to individual patients, as the 3D models generated are tailored to each patient's coronary anatomy and blood flow.

Arterys provides cloud-based Al platforms for analyzing medical imaging, including cardiac MRI and CT scans. The company uses deep learning models to assist radiologists and cardiologists in diagnosing heart diseases. Arterys uses deep learning and neural networks extensively in its AI-powered

## Customer Segments

**Primary Customers:** Healthcare providers (cardiologists, radiologists, general practitioners), health systems, and clinics focused on women's health and preventative cardiology.

**Secondary Customers:** Female smokers developing a risk of heart attack.

• **Female adults (20-59 years)** with risk of heart disease due to factors such as diabetes, obesity, and smoking. They often face challenges like high cholesterol and sedentary lifestyles, making this a crucial time for intervention to prevent serious health issues.

#### User Personas

#### Persona: Lucia Bianchi Persona: Dr. Sarah Name: Dr. Sarah Anderson Name: Lucia Bianchi **Age:** 45 **Age:** 58 **Occupation:** Cardiologist **Occupation:** School Teacher • **Location:** Athens, Grece Education: Bachelor's Degree in • Education: MD in Cardiology, Fellowship Education in Cardiovascular Imaging • **Location:** Athens, Grece **Professional Experience:** 20 years in **Status:** Divorced, mother of one adult son diagnosing and treating heart diseases, with a specific focus on women's heart **Pain Points/Frustrations:**

#### **Pain Points:**

health

1. Missed Early Signs: Traditional diagnostic methods often miss subtle early signs of coronary artery disease (CAD), such as inflammation in coronary arteries, especially in high-risk groups like female smokers.

Personal Background: Dedicated to

disease, particularly in underdiagnosed

improving early detection of heart

groups like female smokers.

- 2. **Limited Tools:** Current diagnostic tools don't provide tailored analysis for women smokers, and there are no efficient ways to visualize early abnormalities.
- **3. Comparative Data:** Difficulty comparing diagnostic data of smokers vs. nonsmokers to highlight meaningful differences in coronary health.

#### **Needs:**

**1. Al-Assisted Detection:** Dr. Sarah needs an Al-powered tool that can detect early signs of coronary inflammation, which are

- 1. Frustrated with generic medical advice that doesn't address her specific risks as a female smoker.
- Has struggled for years to quit smoking but finds it difficult due to stress from her job and personal life.
- 3. Feels overwhelmed by the complexity of making lifestyle changes (e.g., diet and exercise) and doesn't know where to start.

#### **Needs:**

- **1. Longevity:** Wants to live a long and healthy life to be there for her son and future grandchildren.
- 2. **Healthy:** Motivated by the possibility of reducing her risk of heart disease and avoiding the health issues that run in her family.
- 3. **Risk Assessment Support:** Interested in technology and diagnostic tools that provide clear and actionable feedback to make the process of improving her health easier.

#### **Challenges:**

4. Quitting smoking after decades of habit is her biggest challenge.

#### Persona: Dr. Sarah

often invisible through manual analysis of CT scans.

- 2. Comparative Analysis: She requires a system that can highlight key differences between the CT scans of smokers and non-smokers, helping her make more precise diagnoses.
- **3. Risk Assessment Support:** She wants to generate reliable, data-driven risk assessments to inform treatment plans and make earlier intervention decisions.

#### **Challenges:**

- Dealing with diagnostic ambiguity when it comes to early heart disease detection in women, as traditional tools fail to address gender-specific risks.
- Managing high volumes of patient data efficiently while maintaining accuracy in diagnosing subtle early heart issues.

#### **How VivaHeart.AI Solves Her Problems:**

- Al Image Analysis: VivaHeart.Al's advanced image recognition technology analyzes cardiac CT scans, detecting earlystage inflammation and other signs of heart disease.
- Smoker vs. Non-Smoker Comparison: The AI system compares the CT scan of female smokers with non-smokers, enabling Sarah to see the effects of smoking on coronary health.
- Real-Time Risk Assessment: The tool generates personalized heart disease risk scores based on the patient's scan, providing Sarah with actionable data for early intervention.

#### **Expectations:**

- Accurate Detection: Sarah expects the Al tool to deliver a higher accuracy rate in detecting early heart disease signs compared to traditional methods.
- **Easy Integration:** The tool should easily integrate with her clinic's existing systems and workflows, ensuring seamless use in her daily practice.
- Trustworthy and Explainable AI: Sarah values transparency and expects the system to provide explainable insights that she can easily communicate to her patients.

#### Persona: Lucia Bianchi

- 5. Struggling to incorporate regular exercise into her busy schedule.
- 6. She lacks the motivation to make drastic lifestyle changes and often feels discouraged by the lack of clear direction from her healthcare providers.

#### **How VivaHeart.AI Solves Her Problems:**

 Personalized heart disease risk assessment based on her health data, medical history, and lifestyle habits. This tailored analysis gives her clear insights into her specific risks, offering targeted advice on how to reduce them.

### **Expectations:**

- Needs a diagnostic tool that is specific to her situation as a female smoker, giving her targeted health insights.
- Expects easy-to-understand health recommendations that include practical steps for smoking cessation and managing her cholesterol.
- Desires ongoing support from her healthcare provider, including follow-ups to track her progress and keep her motivated.

## 3. The Problem

#### Use Cases

#### Dr. Sarah (Cardiologist):

## Accurate Early Diagnosis of Heart Disease:

- Goal: Dr. Sarah wants to diagnose early signs of heart disease in female smokers more accurately.
- **Details:** She needs an Al-powered system that can analyze cardiac CT scans and highlight subtle inflammation in the coronary arteries, providing earlier and more reliable diagnoses than current tools.
- Tailored Risk Assessments for Female Smokers:
  - Goal: Dr. Sarah wants to generate detailed risk assessments for her female smoker patients, considering their unique risk profiles.
  - **Details:** She requires an AI tool that not only detects early signs of heart disease but also factors in gender-specific risks and smoking habits to create a comprehensive risk assessment for each patient.
- Data Comparison Between Smokers and Non-Smokers:
  - Goal: Dr. Sarah aims to compare the cardiac health of smokers and non-smokers to gain better insights into the effects of smoking on heart health.
  - Details: She needs a system that can compare diagnostic data between these two groups, helping her better understand and communicate the long-term

### Lucia Bianchi:

#### Early Detection of Heart Disease:

- Goal: Lucia wants to detect any early signs of heart disease before symptoms become severe, especially since she is a long-term smoker at higher risk.
- Details: She needs an AI-based tool that can analyze her cardiac CT scans and provide early warnings of coronary inflammation or blockages that might go unnoticed with traditional diagnostics.

#### Personalized Health Insights:

- Goal: Lucia wants personalized health recommendations based on her specific risk factors (smoking history, age, lifestyle).
- Details: She needs a system that tracks her health metrics and offers actionable insights on how to reduce her heart disease risk, such as tips on smoking cessation, diet, and exercise.

#### Smoking Cessation Support:

- Goal: Lucia is trying to quit smoking and needs continuous support to stay motivated and on track.
- Details: She requires real-time feedback and progress tracking on how quitting smoking is improving her heart health, along with personalized tips to help her successfully quit.

Dr. Sarah (Cardiologist):	Lucia Bianchi:
effects of smoking on coronary	
health	

#### Pain Points

#### Dr. Sarah (Cardiologist): **Lucia Bianchi: Diagnostic Limitations:** Current diagnostic tools Missed Early Detection: Traditional miss subtle signs of coronary inflammation and diagnostic tools often fail to detect early early heart disease in female smokers, making it signs of heart disease specific to female challenging to intervene. smokers, leaving her uncertain about her **Limited Comparative Data:** It is difficult to heart health until it's too late for compare diagnostic data between smokers and preventive action. non-smokers in a way that highlights meaningful Lack of Personalization: Lucia struggles differences, limiting her ability to make precise to find health recommendations that are tailored to her specific risks as a female diagnoses. o **Overloaded with Data:** Dr. Sarah often handles smoker, making it difficult for her to take large amounts of patient data without an efficient meaningful steps to improve her heart system that pinpoints actionable insights, making health. it harder to provide timely interventions for at-risk **Difficulty Quitting Smoking:** Without ongoing support or tailored interventions, patients. **Diagnostic Limitations:** Current diagnostic tools Lucia finds it hard to quit smoking, miss subtle signs of coronary inflammation and increasing her long-term risk of heart early heart disease in female smokers, making it disease. challenging for Dr. Sarah to intervene early and offer preventive treatment. Limited Comparative Data: Dr. Sarah finds it difficult to compare diagnostic data between smokers and non-smokers in a way that highlights meaningful differences, limiting her ability to make precise diagnoses. Overloaded with Data: Dr. Sarah often handles large amounts of patient data without an efficient system that pinpoints actionable insights, making it harder to provide timely interventions for at-risk patients.

#### Problem Statement

**Lucia Bianchi**, a 58-year-old smoker, worries about her heart health but struggles to find tailored diagnostic tools that detect early signs of heart disease specific to female smokers.

**Dr. Sarah**, a cardiologist, faces challenges in identifying subtle coronary inflammation in her female patients, as current diagnostics often miss early indicators in high-risk groups like female smokers.

Both need a more effective, AI-assisted solution to provide early, accurate detection and personalized insights for better heart health outcomes.

## Hypotheses and Mission Statement

By bringing **VivaHeart.AI** to life, it **will make early detection of heart disease easier, more personalized, and more accurate for female smokers**. VivaHeart.AI's AI system will empower patients and healthcare providers to make informed, data-driven decisions, leading to earlier interventions, better treatment outcomes, and improved long-term heart health.

## 4. The Solution

#### Ideation

List of all ideas / features that could solve the prioritized pain point(s).

#### **AI-Powered Early Detection for Female Smokers:**

- **Feature:** Al-driven analysis of cardiac CT scans.
  - Solution: Use advanced AI models, such as convolutional neural networks (CNNs), to detect subtle signs of coronary artery disease, such as inflammation or early plaque buildup, which may be missed by traditional diagnostics.
  - Pain Point Solved: Missed early detection in female smokers (for both Lucia and Dr. Sarah).

#### **Personalized Risk Assessments:**

- **Feature:** AI-based personalized heart disease risk calculator.
  - Solution: Generate dynamic risk assessments based on Lucia's smoking habits, medical history, lifestyle factors, and real-time health data, which will update as her habits and health data change.
  - o **Pain Point Solved:** Lack of tailored health recommendations (for Lucia).

#### **Comparative Analysis Between Smokers and Non-Smokers:**

- **Feature:** Visual comparison tool for smokers vs. non-smokers.
  - o **Solution:** The AI system compares Lucia's CT scan with baseline data from non-smokers to highlight differences in heart health and smoking-induced damage.
  - Pain Point Solved: Difficulty comparing diagnostic data of smokers and non-smokers (for Dr. Sarah).

#### **Real-Time Health Monitoring:**

- **Feature:** Integration with wearable devices for real-time heart health tracking.
  - o **Solution:** Sync with wearables like Fitbit or Apple Watch to monitor heart rate, physical activity, sleep, and stress levels. Provide Lucia and Dr. Sarah with immediate feedback on how lifestyle changes (like exercise or stress reduction) are impacting heart health.
  - o **Pain Point Solved:** Difficulty in real-time tracking of health metrics to prevent heart disease (for Lucia and Dr. Sarah).

#### **Integration with Healthcare Providers:**

- **Feature:** Seamless integration with EHRs (Electronic Health Records) and healthcare provider tools.
  - Solution: Allow Dr. Sarah to upload and analyze Lucia's data seamlessly within the system, integrating it with existing medical records, so she can track progress and adjust treatment plans accordingly.
  - Pain Point Solved: Difficulty managing large amounts of patient data efficiently (for Dr. Sarah).

#### **Predictive Alerts and Early Intervention:**

- **Feature:** Predictive alerts based on health changes.
  - Solution: Set up predictive alerts for when Lucia's heart disease risk reaches a critical level based on her data. This can warn both Lucia and Dr. Sarah to take immediate action before her condition worsens.
  - Pain Point Solved: Difficulty identifying high-risk moments and taking preventive action in time (for both Lucia and Dr. Sarah).

## Leveraging Al

Al is essential for VivaHeart.Al because the complexity of diagnosing heart disease, particularly in female smokers, requires a level of precision and personalization that traditional methods and manual analyses often cannot provide. Al excels at processing and analyzing large amounts of medical data, such as cardiac CT scans and real-time health metrics, with accuracy and speed that surpasses manual methods.

**Early Detection of Subtle Signs:** Traditional diagnostic tools often miss subtle early signs of heart disease, such as minor inflammation or small blockages in coronary arteries, especially in women smokers. AI-powered image analysis, using Convolutional Neural Networks (CNNs), can detect these subtle indicators in cardiac CT scans that are difficult for human eyes to spot. This leads to earlier diagnosis and intervention, which is critical for preventing severe heart conditions.

**Personalization at Scale:** Women smokers have unique risk factors that require personalized risk assessments. Generic health recommendations don't adequately address their specific needs. Al algorithms can analyze large sets of personalized data, including medical history, smoking habits, lifestyle factors, and real-time health metrics, to create tailored risk assessments and health plans.

**Predictive Health Alerts:** Identifying when a patient's heart disease risk is reaching a critical point requires continuous data monitoring and predictive analysis, which can be overwhelming for healthcare providers to manage manually. Al can process real-time data and detect when a user's health metrics are signalling potential danger, such as a rise in heart rate or other critical changes. It can trigger predictive alerts to warn both the patient and the healthcare provider.

### • Feature Prioritization

Use the RICE framework to prioritize your features and solutions

Feature	<b>Reach</b> 1-100% of your target user persona	<b>Impact</b> (1-10)	Confidence (1-10)	<b>Effort</b> (1-10)	<b>Score</b> (R x I x C) / E	Priority
AI-Powered Early Detection	90%	9	9	8	91.13	1st
Personalized Risk Assessments	85%	8	9	7	87.43	2nd
Comparative Analysis	75%	7	8	7	60	4th
Smoking Cessation Support	80%	8	8	6	85.33	3rd
Real-Time Health Monitoring	70%	9	8	8	63.00	5th
Explainable AI(XAI)	80%	9	9	7	82.29	3rd
Health Progress Reports	60%	6	7	6	42.00	7th
Predictive Health Alerts	75%	9	8	8	67.50	4th
Integration with Healthcare providers	50%	8	7	7	40.00	8th

#### AI MVP

#### 1. Core Objective:

 The AI MVP will focus on analyzing cardiac CT scans to detect early-stage coronary artery disease (CAD), particularly inflammation or blockages in the arteries that are common in female smokers but often missed by traditional diagnostic methods.

#### 2. Input Data:

- o Medical Imaging (Cardiac CT scans): The AI model will take CT scan images as input to identify early signs of heart disease, especially inflammation in coronary arteries.
- User-Provided Health Data: Supplemental data such as smoking history, age, cholesterol levels, and other lifestyle factors will be integrated to enhance prediction accuracy.

- 3. Techniques and Model Architecture (High Level):
  - o Convolutional Neural Networks (CNNs):
    - CNNs are highly effective for medical image analysis, as they are designed to
      detect patterns and anomalies in image data. In this case, the CNN will be trained
      to identify coronary inflammation, plaque buildup, and early blockages in female
      smokers' CT scans.
- 4. Supervised Learning (for Risk Prediction):
  - To provide a risk score based on the CT scan analysis, the model will use supervised learning (historical data) to predict the likelihood of heart disease based on the identified patterns in the scan, combined with other health data such as smoking history and cholesterol levels. E.g., Heart attack (1=Yes), Heart Attack (0=No)

## Roadmap

## **MVP Product Roadmap**





#### Phase 1: MVP Development (Months 1-3)

- **Duration:** January March
- High-Level Features:
  - o AI-Powered Early Detection (Cardiac CT Scan Analysis):
    - Develop the core AI model using Convolutional Neural Networks (CNNs) to detect coronary inflammation and early signs of heart disease in female smokers.
  - Risk Assessment Model:
    - Integrate a supervised learning model that generates personalized heart disease risk scores based on scan analysis, smoking history, and other health factors.
  - o Initial Data Integration:
    - Set up the system to handle **user-provided health data** and integrate it with the AI model for improved prediction accuracy.
  - Explainable AI (XAI):

• Develop an interface for Dr. Sarah (cardiologists) to interpret the Al's predictions with visual heatmaps and detailed explanations.

#### • Key Milestones:

- o Complete data collection (CT scan data and user health profiles).
- o Initial model training on cardiac CT scan data.
- o Build basic UI for users and healthcare providers to upload data and review results.

#### Phase 2: Pilot Testing & User Feedback (Months 4-6)

• **Duration:** April – June

## • High-Level Features:

#### Pilot Program:

o Roll out the MVP to a select group of users (e.g., female smokers like **Lucia Bianchi**) and healthcare professionals (e.g., cardiologists like **Dr. Sarah**) to gather feedback on usability and performance.

#### Comparative Analysis Feature:

 Allow for side-by-side comparison of CT scans from smokers and non-smokers, highlighting differences in coronary health.

#### Smoking Cessation Support:

 Develop and integrate personalized smoking cessation tools, including real-time feedback on progress and health improvements.

#### Key Milestones:

- o Launch the pilot program in targeted markets (e.g., Greece, the U.S.).
- o Gather and incorporate user and doctor feedback to improve the AI model.
- o Refine the interface for better user engagement.

#### Phase 3: Full Feature Development & Refinement (Months 7-9)

• **Duration:** July – September

• High-Level Features:

#### Real-Time Health Monitoring:

o Integrate wearables (e.g., Fitbit, Apple Watch) to track heart rate, activity, sleep, and stress, providing real-time health feedback.

#### • Predictive Health Alerts:

o Implement a predictive alert system that warns users when their health data indicates an increased risk of heart disease, prompting early intervention.

#### Enhanced Explainable AI (XAI):

 Improve the transparency and interpretability of AI-driven predictions, ensuring cardiologists can confidently explain the system's conclusions to their patients.

#### • User Progress Reports:

 Provide users with regular progress updates, showing improvements in heart health, smoking cessation, and lifestyle changes.

#### • Key Milestones:

- o Complete integration with wearable devices for real-time monitoring.
- o Finalize predictive alert system for heart disease risk.
- o Begin refining user dashboards to display real-time data and progress.

#### Phase 4: Soft Launch (Months 10-12)

• **Duration:** October – December


- High-Level Features:
  - Soft Launch in Key Markets:
    - Launch **VivaHeart.AI** in key regions, focusing on female smokers aged 40-60, particularly in high-risk markets like **Grece**, **the U.S.**, and **the U.K.**.
  - Healthcare Provider Integration:
    - Partner with healthcare providers to integrate VivaHeart.Al with Electronic Health
       Records (EHR) systems for seamless data transfer and diagnostics.
  - Feedback Loop for AI Model Improvement:
    - Implement a feedback loop with healthcare professionals to continuously improve the AI model based on real-world use cases and outcomes.
- Key Milestones:
  - o Launch VivaHeart.AI in targeted regions with a focus on early adopters.
  - o Monitor adoption rates, user feedback, and system performance.
  - o Prepare for scaling the product based on soft launch data.

#### Phase 5: Full Market Launch & Scaling (Months 13-18)

- **Duration:** January June (Year 2)
- High-Level Features:
  - Full Global Launch:
    - Expand VivaHeart.AI's availability to additional countries with high rates of smoking and heart disease among women (e.g., France, Canada, Australia).
  - Advanced AI Features:
    - Continue improving the AI model's accuracy with larger datasets and enhanced training techniques, ensuring it generalizes well across diverse populations.
  - Feature Expansion:
    - Introduce new features like personalized **diet recommendations**, **exercise plans**, and **stress management tools** based on user data.
- Key Milestones:
- Achieve global launch and expand partnerships with healthcare providers and insurers.
- Focus on user retention strategies and data-driven product improvements.
- Gather long-term user data to continuously refine predictive algorithms and health insights.

#### Technical Architecture

#### VivaHeart.Al



- Client Layer: Users (e.g., Lucia) and healthcare providers (e.g., Dr. Sarah) interact with VivaHeart.AI through mobile apps or web-based platforms, where they upload health data and CT scans
- **Application Server:** Manages user data, processes requests, and sends data to the AI model for analysis. It retrieves results from the AI and provides them to the users.
- AI Model Layer: Uses Convolutional Neural Networks (CNNs) for image analysis and supervised learning for personalized heart disease risk assessment. It processes CT scans and health data to provide early detection of heart disease.
- **Data Storage:** Secure, cloud-based storage for CT scans, health records, and user data. Data is encrypted and compliant with **HIPAA** and **GDPR** standards.
- **Cloud Infrastructure:** Hosted on platforms like AWS or Google Cloud, ensuring scalability and fast processing using GPU resources for AI models. Includes load balancing and auto-scaling to handle varying user loads.
- **Security and Compliance:** Data is encrypted in transit and at rest. Multi-factor authentication and compliance with healthcare regulations protect user privacy.
- **External Integrations:** Integrates with wearable devices for real-time monitoring and healthcare provider systems (EHRs) for seamless data access.

## Assumptions and Constraints

#### Assumptions:

- 1. Availability of Medical Data: Sufficient access to high-quality, labeled cardiac CT scan datasets and patient data for training and validating the AI models will be available through partnerships with hospitals and healthcare institutions.
- 2. Compliance with Healthcare Regulations: The product will comply with healthcare privacy regulations (e.g., HIPAA in the U.S. and GDPR in Europe), ensuring that personal health data is handled securely.
- 3. User Engagement: Users (e.g., female smokers like Lucia Bianchi) will consistently input their health data and use wearable devices for real-time monitoring, allowing the AI system to provide accurate, personalized insights.
- 4. Cloud Infrastructure Scalability: The chosen cloud infrastructure (AWS, Google Cloud, etc.) will provide the necessary scalability to handle large volumes of data, especially during peak usage times when multiple users upload CT scans.
- 5. Al Model Generalization: The Al models trained on available datasets will generalize well to new users, ensuring that predictions are accurate across different demographics, particularly for female smokers.
- 6. Healthcare Provider Adoption: Healthcare providers (e.g., cardiologists like Dr. Sarah) will integrate VivaHeart.AI into their workflows and trust the AI-based analysis for making early diagnoses and treatment decisions.

#### Constraints:

- 1. Data Privacy and Security Regulations: Strict adherence to data privacy regulations (e.g., HIPAA and GDPR) may limit how data is collected, processed, and shared, especially in terms of storing and accessing sensitive medical data.
- 2. Access to High-Quality Medical Data: Access to large, diverse datasets of cardiac CT scans may be limited due to privacy concerns or data-sharing restrictions, which could impact the AI model's ability to learn and perform well.
- 3. Computational Resources: Processing large cardiac CT scans and real-time data streams from wearables requires significant computational power (e.g., GPU resources), which may increase operational costs and limit real-time processing during peak loads.
- 4. Bias in AI Models: If the training data does not sufficiently represent diverse demographics (e.g., age, gender, smoking habits), the AI model may introduce bias, leading to inaccurate predictions for certain populations.
- 5. Healthcare Integration Complexity: Integrating VivaHeart.AI with existing Electronic Health Record (EHR) systems in hospitals and clinics may require extensive customization and development time, slowing down adoption.

#### Risks

#### **Data Privacy and Security Risks**

• **Risk:** Handling sensitive health data (e.g., cardiac CT scans, personal health information) could expose the product to privacy breaches or regulatory violations (e.g., **HIPAA**, **GDPR** noncompliance).

#### • Mitigation Strategy:

- o Implement **end-to-end encryption** for data storage and transmission.
- Use **multi-factor authentication (MFA)** to ensure secure user access.
- Conduct regular security audits and penetration testing to identify and fix vulnerabilities.
- Strictly comply with HIPAA and GDPR regulations, ensuring that all data is anonymized where possible and user consent is obtained for data use.

#### 2. Insufficient or Biased Training Data

• **Risk:** The AI model may perform poorly if trained on insufficient or biased datasets that do not adequately represent diverse populations, particularly female smokers.

#### • Mitigation Strategy:

- Use a diverse and representative dataset that includes a wide range of demographics (e.g., different age groups, ethnicities, and smoking habits).
- Employ data augmentation techniques to increase the variety of training data, especially for underrepresented groups.
- o Continuously monitor and evaluate the model

#### **Model Accuracy and False Predictions**

• **Risk:** The AI model may produce false positives or false negatives, leading to misdiagnoses or missed early detection of heart disease. This could damage trust in the system and potentially harm users.

#### Mitigation Strategy:

- Use rigorous **testing and validation** phases, with real-world data, to ensure the model performs well before deployment.
- o Incorporate a **confidence threshold** for AI predictions, allowing healthcare providers to review cases where the AI's confidence is low.
- Provide users and healthcare professionals with a **feedback loop** to report incorrect predictions, which will help in improving the model's performance.

#### 4. Regulatory Approval Delays

• **Risk:** Al-driven medical products require approval from regulatory bodies like the **FDA** or **EMA** (European Medicines Agency), and this approval process can delay the product's launch.

#### • Mitigation Strategy:

- Start the **regulatory approval process** early and work closely with legal experts in healthcare regulations.
- Ensure the product is designed to comply with medical device standards and safety guidelines from the outset to minimize delays during the approval process.

 Develop a clear **documentation and testing protocol** to demonstrate the safety, efficacy, and transparency of the AI model to regulators.

#### **High Operational Costs**

• **Risk:** Running AI models, especially for large-scale medical imaging analysis, requires significant computational resources, which could result in high operational costs.

#### • Mitigation Strategy:

- o Optimize AI models to reduce resource consumption without compromising performance.
- Use cloud infrastructure that scales based on demand, minimizing idle resources during low-traffic periods.
- Explore partnerships with healthcare institutions or insurance companies to offset costs, making the service more accessible to users.

## 5. Requirements

### User Journeys

## Dr. Sarah (45-year-old Cardiologist)

#### **Awareness Stage:**

- **Scenario:** Dr. Sarah reads about **VivaHeart.AI** in a medical journal article highlighting new AI tools for early heart disease detection in women.
- Actions: She visits the VivaHeart.Al
  website to learn how the AI can assist in
  identifying early signs of coronary artery
  disease in her high-risk female smoker
  patients.
- **Emotions:** Interested in adopting new technology that could enhance her diagnostic capabilities.

#### **Onboarding Stage:**

- Scenario: Dr. Sarah begins using VivaHeart.Al with a few patients who are at high risk for heart disease, including Lucia Bianchi.
- Actions: She uploads Lucia's cardiac CT scan into the system and reviews the Algenerated analysis. She receives detailed insights on coronary inflammation, allowing her to detect early signs of disease that were previously unnoticed.

#### **Diagnostic Stage:**

• **Scenario:** Dr. Sarah uses VivaHeart.Al to analyze scans from other female patients

#### Lucia Bianchi (58-year-old Female Smoker)

#### **Awareness Stage:**

- Scenario: Lucia reads about heart disease risks for female smokers in an online article and sees a reference to VivaHeart.AI, an AI-powered early detection tool.
- Actions: She visits the VivaHeart.Al
  website to learn more about how it can
  help detect early signs of heart disease
  specific to women like her.
- **Emotions:** Curious, concerned about her health, and motivated to take action to improve her future health outcomes.

### **Onboarding and Data Collection Stage:**

- **Scenario:** Lucia uploads her most recent cardiac CT scan and fills out her health information (e.g., smoking history, family history of heart disease).
- Actions: She uploads her scan and connects her wearable device to track her daily activity, heart rate, and stress levels.
- **Emotions:** Apprehensive, but committed to finding out the status of her heart health.

#### **Diagnostic Stage:**

• **Scenario:** The AI processes her CT scan and health data, identifying early signs of

### Dr. Sarah (45-year-old Cardiologist)

- and compare diagnostic data between smokers and non-smokers.
- Actions: She compares Lucia's scan to that of a non-smoker, using the Al's visualizations to show the impact of smoking on coronary health. She discusses the Al-generated risk assessment with Lucia and outlines a personalized treatment plan based on the data.
- **Emotions:** Confident in the Al's capabilities and pleased with how easily she can explain the results to her patients.

#### Maintenance and Follow-Up Stage:

- Scenario: Dr. Sarah incorporates
   VivaHeart.Al as a regular part of her
   practice for high-risk female smokers,
   using it to assist in early detection and
   ongoing monitoring.
- Actions: She continues to use the AI platform to screen new patients, especially those with high-risk profiles. She shares insights with other cardiologists and presents her findings at medical conferences, advocating for the use of AI in heart disease prevention.
- **Emotions:** Proud of being a leader in adopting innovative technology that improves patient outcomes and supports earlier interventions.

## Lucia Bianchi (58-year-old Female Smoker)

- inflammation in her coronary arteries that were previously undetected.
- Actions: She receives a personalized risk assessment that highlights her elevated risk of coronary artery disease. Algenerated recommendations, including steps to quit smoking, improve her diet, and increase physical activity.
- Emotions: Initially anxious upon receiving the risk assessment, but reassured by the clear guidance and early detection.

#### Maintenance and Follow-Up Stage:

- **Scenario:** Lucia has a follow-up appointment with her cardiologist and continues using VivaHeart.AI for ongoing heart health monitoring.
- Actions: She shares her VivaHeart.Al
   data with her doctor during her check-up,
   showing improvements in her overall risk
   score and health metrics. She continues
   using the app for long-term monitoring,
   receiving periodic progress reports on
   how her lifestyle changes are reducing her
   risk of heart disease.
- **Emotions:** Proud of her accomplishments and relieved that she's taking control of her heart health.

## • Functional Requirements

The core functionality of **VivaHeart.AI** revolves around leveraging AI to provide early detection of heart disease in female smokers, personalized health insights, and real-time health monitoring. Here's a deeper dive into the product's key functionalities and how they will work at a high level.

#### **Cardiac CT Scan Analysis:**

• **Purpose:** To detect early signs of coronary artery disease (CAD), particularly inflammation and blockages in the coronary arteries, which are often invisible through manual diagnostics.

#### How It Works:

- Users (patients like Lucia) will upload their cardiac CT scans via the app or a healthcare provider will upload it through the provider interface.
- The system will automatically analyze the CT scan and identify early signs of heart disease, providing actionable insights for both patients and healthcare providers.

• Why Algorithms Are Needed: Analyzing medical images to detect subtle changes like early-stage inflammation or plaque buildup requires sophisticated algorithms that can process and identify patterns within the imaging data as CNN.

#### **Personalized Heart Disease Risk Assessment:**

• **Purpose:** To provide personalized heart disease risk scores based on the user's health data (e.g., smoking history, cholesterol levels, blood pressure, activity levels).

#### • How It Works:

- Users will input their **health data** through the app, including lifestyle factors, family history, and real-time health data from wearable devices (heart rate, sleep patterns, etc.).
- The system will generate a **personalized risk score** that update over time as new data is collected. This score will reflect the user's probability of developing heart disease based on their unique profile.
- Why Algorithms Are Needed: Risk assessments require algorithms that can interpret complex data sets and accurately assess a user's risk by identifying relationships between health data and heart disease outcomes.

#### **Comparative Analysis Between Smokers and Non-Smokers:**

• **Purpose:** To compare the CT scans and health data of female smokers with non-smokers to highlight the impact of smoking on coronary health.

#### • How It Works:

- Healthcare providers can upload scans from both smokers and non-smokers, and the system will provide a side-by-side comparison of coronary health.
- The comparison highlights differences in coronary artery conditions, such as the presence of inflammation or plaque, allowing doctors to show patients the impact of smoking.
- Why Algorithms Are Needed: This feature requires analyzing multiple datasets simultaneously
  and identifying significant differences between the groups to generate meaningful insights for
  healthcare providers.

#### **Predictive Health Alerts:**

• **Purpose:** To alert users and healthcare providers when their heart disease risk significantly increases, prompting immediate action.

#### • How It Works:

- The system continuously analyzes incoming health data and identifies patterns that suggest an elevated risk of heart disease or an upcoming health event (e.g., heart attack).
- Users and healthcare providers receive **predictive alerts** when the system detects critical health changes, recommending immediate interventions (e.g., seek medical advice, adjust medication).
- Why Algorithms Are Needed: Predictive alerts rely on algorithms that can process time-series data from wearables and other health inputs to anticipate health risks before they manifest as symptoms.

#### **Integration with Healthcare Providers:**

• **Purpose:** To allow healthcare providers to access patient data and use VivaHeart.AI insights in their medical practices.

#### • How It Works:

- Electronic Health Record (EHR) integration enables doctors to view patient data, including CT scan results, risk assessments, and progress reports, within their existing systems.
- Providers can use the AI-generated insights to make more informed diagnoses and treatment decisions for their patients.
- Why Algorithms Are Needed: Integrating patient data with healthcare systems and providing actionable insights requires algorithms that can analyze medical data efficiently while ensuring compliance with healthcare regulations.

## • Non-functional Requirements

#### **Security:**

- **Data Encryption:** All user data, including **medical images (CT scans)**, health information, and personal details, must be encrypted.
- **User Authentication:** Implement **multi-factor authentication (MFA)** to ensure that only authorized users can access sensitive data.
- Access Control: Ensure that only authorized healthcare providers and system administrators have access to sensitive patient data via role-based access control (RBAC).
- **Compliance with Regulations:** The system must comply with **HIPAA** and **GDPR** regulations, ensuring that all sensitive health data is handled and stored securely, with user consent for data use.

#### **Scalability:**

- **Cloud Infrastructure:** The system must be designed to scale horizontally and vertically to handle increases in data processing, user uploads, and real-time monitoring without performance degradation.
- **Auto-Scaling:** Implement auto-scaling to accommodate peak usage times, such as when many users upload **CT scans** or use real-time monitoring tools simultaneously.
- **Support for Global Access:** VivaHeart.AI should be scalable to serve users from multiple geographic locations with low latency, ensuring global availability.

#### **Performance:**

- Real-Time Processing: The system must process cardiac CT scans and real-time health data (from wearables) quickly, providing results within a few seconds to ensure a seamless user experience.
- **Low Latency:** The system must maintain a maximum response time of **2-3 seconds** for core features, such as displaying diagnostic results and generating risk assessments.

- **High Availability:** The platform must have an uptime of **99.9%** or higher to ensure continuous service, minimizing downtime and service interruptions.
- **Throughput:** The platform should support a large number of simultaneous users (e.g., thousands of users uploading scans at once) without performance issues.

#### **Usability:**

- Intuitive User Interface: The app's interface must be easy to navigate for both patients (e.g., Lucia Bianchi) and healthcare professionals (e.g., Dr. Sarah), with clear, understandable data visualizations and reports.
- **Accessibility:** The platform must comply with accessibility standards, ensuring that users with disabilities can access and use the platform effectively.
- Multi-Language Support: The app must support multiple languages (e.g., English, Italian,
   Spanish) to cater to users from different regions.
- **Mobile Optimization:** The app must be fully optimized for mobile devices, ensuring smooth performance on iOS and Android platforms, regardless of device specifications or screen sizes.

#### Maintainability:

- **Modular Architecture:** The system's codebase must be modular, allowing for easy updates, bug fixes, and feature expansions without disrupting the overall service.
- **Automated Testing:** Implement automated testing protocols to ensure new features or updates do not introduce regressions or bugs into the system.
- **Documentation:** Provide comprehensive technical documentation for developers, system administrators, and healthcare providers to ensure easy onboarding, troubleshooting, and maintenance.

#### **Reliability:**

- **Fault Tolerance:** The system must be designed with fault tolerance in mind, ensuring that failures in one part of the system (e.g., a server outage) do not cause a full system failure. **Redundant servers** and failover mechanisms should be in place.
- **Backup and Recovery:** The system must automatically back up critical user data and support data recovery within a **24-hour** timeframe in the event of data loss or system failure.
- **Error Handling:** Implement comprehensive error handling to gracefully handle any issues (e.g., failed uploads) and provide users with clear instructions on how to resolve problems.

#### Interoperability:

- **API Integration:** The system must support secure API integration with external healthcare platforms, such as **Electronic Health Records (EHR)**, using industry standards like **HL7** and **FHIR**.
- **Wearable Device Compatibility:** The system must integrate with popular wearable devices (e.g., **Fitbit**, **Apple Watch**) to gather health metrics such as heart rate, physical activity, and sleep data.
- **Cross-Platform Support:** VivaHeart.Al must support both desktop and mobile environments, ensuring users can access the system from multiple devices seamlessly.

#### **Data Privacy:**

- **User Consent:** The system must obtain explicit user consent for data collection and usage, especially when handling sensitive medical data, in compliance with privacy regulations.
- **Data Anonymization:** For any shared or processed data that is used for research purposes or shared with third parties, user data must be **anonymized** to protect personal information.
- **Data Retention Policy:** Implement clear data retention policies to ensure that personal data is stored only for as long as necessary, and that it is securely deleted afterward, in line with regulatory guidelines.

#### Portability:

- **Cloud-Agnostic Architecture:** The system should be designed to be cloud-agnostic, allowing for easy migration between cloud platforms (e.g., from **AWS** to **Google Cloud**) if necessary.
- **Device Compatibility:** The platform must be compatible with a range of devices (e.g., smartphones, tablets, desktops) and browsers to ensure a broad user base can access the service.

#### **Compliance:**

- **Regulatory Compliance:** The product must adhere to relevant healthcare regulations, including **HIPAA** (U.S.) and **GDPR** (Europe), ensuring patient data privacy and security.
- **Medical Device Certification:** If required, obtain certifications from relevant bodies (e.g., **FDA**) to ensure that VivaHeart.AI is recognized as a safe, reliable medical device for heart disease detection.

## • Al & Data Requirements

For **VivaHeart.AI** to function effectively and provide accurate heart disease risk assessments and early detection for female smokers, the AI system requires access to a variety of **data sources** and **data types**. These will drive the AI model's performance and enable personalized health insights. The data must be carefully managed to ensure compliance with healthcare regulations and maintain data integrity.

#### 1. Data Sources:

#### 1.1. Cardiac CT Scan Data

- **Type:** Medical imaging (unstructured data)
- Description:
  - Cardiac CT scans are essential for detecting early signs of coronary artery disease (CAD),
     such as inflammation, calcification, and blockages in the arteries.
  - The AI model will analyze these images to identify early-stage heart disease that may be missed by manual inspection.

#### • Data Collection Process:

 Users upload their CT scans via the VivaHeart.Al app or through healthcare providers who use the platform. Integration with PACS (Picture Archiving and Communication System) in hospitals may be needed to access patient scans.

### • Data Management:

 Medical imaging data must be stored securely in **DICOM format** with encrypted access controls, ensuring compliance with **HIPAA** and **GDPR** standards.

#### 1.2. Wearable Device Data

• **Type:** Structured health metrics (time-series data)

#### • Description:

 Data from wearable devices (e.g., Fitbit, Apple Watch) includes heart rate, steps, activity levels, sleep patterns, and stress levels. This real-time data is critical for tracking lifestyle factors that impact heart health.

#### • Data Collection Process:

 Users connect their wearables to the VivaHeart.AI platform using API integrations to sync real-time health metrics.

#### • Data Management:

 Time-series data is stored in the cloud, with daily, weekly, and monthly summaries generated for both users and healthcare providers.

#### 1.3. User-Provided Health Data

• **Type:** Structured demographic and health data

#### • Description:

 Users provide information such as age, weight, height, smoking habits, cholesterol levels, family history, physical activity, diet, and existing health conditions.

#### Data Collection Process:

 Collected during user onboarding and updated periodically as users interact with the app (e.g., smoking cessation updates, exercise routines).

#### • Data Management:

 User data is stored securely in a cloud database, and it is continuously updated as users input new information. Data must be encrypted to protect personal health information (PHI).

#### 1.4. Electronic Health Records (EHR) and Lab Results

• **Type:** Structured medical records and lab data

#### Description:

 Medical records, including lab results such as cholesterol levels, blood pressure, and triglycerides, will be incorporated to refine risk assessments and provide deeper insights into users' cardiovascular health.

#### • Data Collection Process:

o Integration with **EHR systems** using standardized APIs (e.g., **FHIR**, **HL7**) will allow users and healthcare providers to upload lab results or retrieve them from existing systems.

#### • Data Management:

 Medical records and lab results are stored alongside other user data in an encrypted database, accessible only to authorized users.

#### 2. Types of Data Required:

#### 2.1. Medical Imaging Data (Cardiac CT scans)

• **Description:** High-resolution images that capture detailed views of the coronary arteries, enabling the AI to detect early signs of disease.

- **Format: DICOM** (Digital Imaging and Communications in Medicine) format is the standard for medical imaging data.
- **Role in AI:** The AI model will use this data to identify patterns, such as inflammation or plaque buildup, indicative of early coronary artery disease (CAD).

#### 2.2. Health Metrics from Wearables

- **Description:** Continuous tracking of health indicators such as **heart rate**, **physical activity**, **sleep**, and **stress levels**.
- Format: JSON/CSV or other time-series formats generated by wearable devices.
- **Role in AI:** This real-time data helps monitor lifestyle factors and provides additional context for the risk assessment model, allowing for real-time alerts and personalized recommendations.

#### 2.3. Demographic and Health Profile Data

- **Description:** Information provided by users about their health and lifestyle habits, including age, weight, smoking history, family history of heart disease, and physical activity levels.
- **Format:** Structured data (forms and input fields in the app).
- **Role in AI:** This data is used in the AI's risk prediction model to assess a user's heart disease risk based on known risk factors for female smokers.

#### 2.4. Lab Results and EHR Data

- **Description:** Medical history and lab results (e.g., cholesterol, triglycerides, blood pressure) from healthcare providers, offering deeper insights into a user's current health condition.
- **Format:** HL7/FHIR standards for electronic health data exchange or manually input lab results.
- **Role in AI:** Lab results are crucial for validating the AI model's predictions and improving the accuracy of risk assessments, especially in cases of elevated cholesterol or other heart disease markers.

#### 3. Data Collection and Management Processes:

#### 3.1. Data Collection:

#### • User Inputs:

Users manually enter their health data (e.g., smoking habits, physical activity) and upload
 CT scans through the app.

#### • Automated Data Collection:

o Wearable devices automatically sync real-time data with VivaHeart.Al's cloud platform.

#### EHR Integration:

 Medical records and lab results are retrieved from healthcare providers using APIs and uploaded to the platform for analysis.

#### 3.2. Data Storage and Privacy:

#### Data Storage:

 All data is securely stored in the cloud using encrypted databases and storage systems such as AWS S3 or Google Cloud Storage. Medical imaging data is stored in PACScompliant systems.

#### • Data Privacy:

 To ensure compliance with HIPAA and GDPR, all sensitive health data must be encrypted in transit and at rest. Users must provide explicit consent for data use.

#### Data Anonymization:

 Before using any data for research or AI model improvement, it must be anonymized to remove any personally identifiable information (PII).

### 4. AI Model Data Requirements:

#### 4.1. Training Data:

- **Cardiac CT scans:** A large dataset of **labeled CT scans** is required to train the Al model on recognizing early signs of coronary artery disease in smokers.
- **Health and Demographic Data:** Historical health data (e.g., smoking habits, cholesterol levels) from previous patients is needed to train the model for personalized risk assessments.

#### 4.2. Validation Data:

• The AI system must be validated with real-world data, including new CT scans and updated health profiles, to ensure its predictions generalize across a wide range of users.

#### 5. Data Management and Compliance:

#### **5.1. Compliance with Healthcare Regulations:**

• **HIPAA** and **GDPR** compliance are mandatory to protect user privacy and ensure the ethical use of health data. VivaHeart.Al must provide users with control over their data and inform them about how it is used.

#### 5.2. Data Access and Retention:

• Users must have full control over their health data, with the ability to delete or export their data at any time. Data retention policies must be transparent, with unnecessary data being deleted after a specific retention period to comply with legal standards.

## 6. Challenges

#### **Data Availability and Quantity**

#### • Challenge:

- Acquiring a large enough dataset of cardiac CT scans, health metrics, and usergenerated data (such as smoking history, cholesterol levels) may be difficult, particularly for female smokers, who are a specific target group.
- Medical data is often siloed in healthcare institutions, and there may be restrictions on accessing and sharing sensitive patient data due to HIPAA and GDPR regulations.

#### • Plan to Acquire Data:

- Healthcare Partnerships: Establish partnerships with hospitals, clinics, and diagnostic imaging centers to acquire anonymized cardiac CT scans and health data. Collaboration with cardiologists will be key to gaining access to larger datasets.
- Publicly Available Datasets: Leverage open medical imaging datasets such as NIH or UK
   Biobank to supplement initial training.
- User Contributions: Encourage users to upload their own CT scans and health data in exchange for personalized risk assessments. Provide clear value propositions to motivate users to share data.

 Data Sharing Agreements: Work with healthcare institutions to create secure datasharing agreements that comply with privacy regulations while providing the necessary datasets for training and improving the AI models.

### 2. Funding for AI Development and Data Acquisition

#### Challenge:

 Training AI models, acquiring medical data, and integrating healthcare systems require significant **financial resources**. Securing enough funding to support these efforts is crucial for the success of VivaHeart.AI.

#### • Plan to Address Funding Needs:

- Venture Capital Funding: Seek investment from venture capital firms focused on healthcare technology and AI solutions. Highlight the unique value proposition of early detection for female smokers, a high-risk group, to attract interest.
- o **Grants and Research Funding:** Apply for government or healthcare innovation grants that support AI-driven solutions in healthcare. This can provide additional resources for data acquisition and model development.
- Strategic Partnerships: Partner with healthcare providers and insurance companies to
  offset data collection and model development costs. Insurance companies, in particular,
  have an incentive to invest in early detection tools that reduce long-term healthcare costs.
- o **Crowdsourced Data Contributions:** Develop incentives (e.g., premium features, personalized reports) to encourage users to contribute their own medical data to the platform, reducing the cost of acquiring proprietary data.

#### 3. User Conviction and Adoption

#### • Challenge:

 Convincing both patients (like Lucia Bianchi) and healthcare providers (like Dr. Sarah) to trust and adopt AI-based diagnostics, especially for critical conditions like heart disease, may be difficult. AI in healthcare is still viewed with some skepticism, especially when it comes to replacing or augmenting traditional diagnostic methods.

#### Building User Conviction:

- Explainable AI (XAI): Incorporate explainable AI features that provide clear, understandable explanations for how the AI arrived at its conclusions, building trust with healthcare providers and patients alike.
- Pilot Programs: Run pilot programs with healthcare institutions and female smokers to demonstrate the effectiveness of VivaHeart.AI in detecting early signs of heart disease.
   Collect testimonials and case studies to prove its value in real-world settings.
- User Education: Provide educational resources that explain how AI works in healthcare, particularly how it enhances diagnostics and improves early detection. This will build confidence in AI's ability to provide reliable and actionable insights.
- o **Physician Endorsements:** Encourage early adopters in the medical field to endorse the product and use their experiences to promote trust among potential users.
- Continuous Feedback: Implement a feedback loop that allows users and healthcare professionals to report on the AI's accuracy and usability. Use this feedback to improve the product and prove its effectiveness.

## 7. Positioning

Use Case	Pain Point	Possible Solutions	Impact of Solution
Early Detection of Heart Disease	Traditional diagnostic tools miss early sings of heart disease in female smokers	AI-powered analysis of cardiac CT scans to detect inflammation and blockages early	Preventative measurements, reducing risk of severe heart disease and improving survival rates.
Personalize Risk Assessment	Generic health advice does not address the specific risk of female smokers	Al-driven heart disease risk scores based on user health data, smoking habits, and real time metrics	Tailor recommendations, empowering users to take proactive steps to reduce their risk
Smoking Cessation Support	Difficulty quitting smoking due to lack of personalized guidance and motivation	Personalized smoking cessations tools, progress tracking, motivational tips, health improvement	Increase chances of quitting smoking, leading to a reduce risk of heart disease and overall better heath outcomes
Comparative Analysis (smokers vs. Non- Smokers)	Difficulty in showing patients the direct impact of smoking on coronary health	Al based comparative analysis of smokers vs. nonsmokers with visualization differences	Help educate users on specific impact of smoking motivating lifestyle changes and supporting early interventions.
Predictive Health Alerts	Users are unaware of when their risk of heart attack spikes	Al driven predictive alerts based on real time data analysis, warning users and health cate providers of elevated risk	Early warnings to prevent heart attacks or other heart conditions with a timely intervention

## 8. Measuring Success

#### Metrics

To measure the success of **VivaHeart.AI** as a product, the following **Product Management (PM) metrics** are needed:

#### • Early Detection Success Rate:

 The percentage of female smokers who receive an early diagnosis of heart disease risk (e.g., coronary artery inflammation or other early indicators) through the use of VivaHeart.Al's Al-powered CT scan analysis, leading to timely medical intervention.

#### • User Engagement:

- Daily Active Users (DAU): The number of users actively using VivaHeart.Al on a daily basis.
- Time Spent in App: Average time users spend interacting with the app, such as viewing health insights, uploading CT scans, or tracking progress.
- **Feature Usage Rate:** Percentage of users engaging with core features (e.g., CT scan uploads, smoking cessation tools, real-time monitoring).

#### User Retention:

- o **30-Day Retention Rate:** Percentage of users who return to the app 30 days after signup.
- o **Churn Rate:** The percentage of users who stop using the app over a given period.
- **Stickiness:** The ratio of **DAU/MAU** (Monthly Active Users), indicating how frequently users return to the app.

#### • Health Outcomes Improvement:

- o **Smoking Reduction:** Percentage of users who reduce or quit smoking after using the app.
- Improvement in Key Health Metrics: Percentage of users with improvements in cholesterol, blood pressure, and physical activity levels.

#### • Customer Satisfaction:

- Net Promoter Score (NPS): Measures how likely users are to recommend VivaHeart.Al to others
- Customer Satisfaction Score (CSAT): Measures users' satisfaction with the app and its features.
- App Store Ratings: The average rating the app receives on platforms like iOS and Android

## • Al-specific Metrics

Quality for **VivaHeart.AI** from an AI perspective means delivering **accurate**, **explainable**, **and actionable insights** that help users (e.g., Lucia) and healthcare providers (e.g., Dr. Sarah) detect early signs of heart disease and make informed decisions.

#### **AI-Specific Metrics:**

#### Model Accuracy:

- Precision: The percentage of correctly identified positive cases (e.g., identifying true coronary inflammation in CT scans).
- **Recall (Sensitivity):** The ability of the model to correctly identify all true positive cases (e.g., catching all potential cases of early heart disease).
- o **F1 Score:** A balance between precision and recall, giving an overall performance score.
- o **Target:** Minimum **90%** precision and recall for heart disease detection before launch.

#### • False Positive/Negative Rate:

- o **False Positive Rate:** Percentage of users incorrectly flagged as having heart disease.
- False Negative Rate: Percentage of users with heart disease that the model fails to detect. This must be kept below 5% to minimize undiagnosed cases.

#### Model Interpretability (Explainable AI):

- **Explainability Score:** Percentage of AI predictions that are accompanied by clear, understandable visual explanations (e.g., heatmaps on CT scans).
- Healthcare Provider Feedback: Percentage of healthcare providers who trust and validate Al-generated insights.

#### • Model Latency:

- o **Prediction Time:** The time taken by the AI to analyze a CT scan and return insights. Target is **5 seconds or less** for an initial diagnosis.
- Real-Time Processing: The system's ability to process real-time data (e.g., from wearables) and provide immediate feedback within 2 seconds.

#### • Bias and Fairness:

- o **Fairness Metrics:** Ensuring that the model performs equally well across diverse demographics, such as age groups, ethnicities, and gender.
- Bias Audits: Regular bias audits to ensure the model does not disproportionately affect any user group.

## • What is your North Star Metric?

The North Star Metric for VivaHeart.AI is the Percentage of Users who Achieve a Significant Reduction in Heart Disease Risk after 6 months of using the platform.

- This metric captures the ultimate goal of VivaHeart.AI: to help users (especially female smokers like Lucia) detect heart disease early and reduce their risk through personalized interventions.
- By focusing on risk reduction, this metric ties directly to **real-world health outcomes**, ensuring that the product delivers measurable improvements in users' heart health.

#### **Early Detection Success Rate:**

• The percentage of female smokers who receive an early diagnosis of heart disease risk (e.g., coronary artery inflammation or other early indicators) through the use of VivaHeart.Al's Alpowered CT scan analysis, leading to timely medical intervention.

## 9. Launching

### • Stakeholders & Communication

#### **Key Stakeholders:**

#### • Internal Stakeholders:

- Product Team: Ensures development aligns with the product vision, timeline, and user needs
- o **Al/Data Science Team:** Focuses on improving Al model performance and accuracy.
- Engineering Team: Manages the platform's infrastructure and integration with external systems.
- Compliance & Legal Team: Ensures adherence to healthcare regulations like HIPAA and GDPR.
- o Marketing & Sales Team: Develops go-to-market strategies and user acquisition plans.

#### • External Stakeholders:

- Healthcare Providers (Cardiologists like Dr. Sarah): Provide feedback on diagnostic accuracy and usability in medical settings.
- o **Patients (Users like Lucia Bianchi):** End-users who rely on the platform for early heart disease detection and personalized insights.
- Investors/Board Members: Interested in the product's market fit, scalability, and financial performance.
- Regulatory Bodies (FDA, EMA): Ensures compliance with medical standards and approves the use of AI for diagnostic purposes.

0

#### **Communication Plan:**

#### 1. Development Phase (Pre-launch):

- o **Internal Updates:** Weekly stand-ups for the product, engineering, and AI teams to align on progress, technical challenges, and feature priorities.
- Stakeholder Reports: Monthly progress reports to key internal and external stakeholders, outlining feature development, testing results, and milestones achieved.
- User Testing Updates: Regular updates to early adopters (users and healthcare providers) participating in pilot testing to gather feedback and fine-tune product features.

#### 2. Pre-Launch Phase:

- Healthcare Provider Outreach: Host webinars and training sessions to educate healthcare providers on using VivaHeart.Al for diagnostic purposes, emphasizing Explainable Al and how it supports early detection.
- User Engagement Emails: Begin sending email campaigns to users like Lucia to introduce new features, benefits, and onboarding instructions.
- o Investor Briefings: Quarterly investor briefings detailing the progress toward product launch, AI model performance, and the roll-out strategy.

#### 3. Post-Launch (Public Release):

 Launch Announcements: Public launch via press releases, social media, and email marketing. Highlight partnerships with healthcare providers and successful pilot testing results.

- Ongoing Feedback: Establish continuous feedback loops via in-app surveys, user feedback forms, and regular discussions with healthcare providers to iterate on and improve features.
- o **Performance Dashboards:** Provide stakeholders with access to real-time performance dashboards showing key metrics (user engagement, AI accuracy, user satisfaction).

## Roll-out strategy

#### **Strategic Considerations for Go-to-Market:**

#### 1. Target Audience:

- o Initial focus on female smokers aged 40-60, as they are at higher risk of heart disease.
- Geographic focus: Start with regions where smoking rates among women are high (e.g., Grece, Germany and Spain).

#### 2. Healthcare Provider Partnerships:

- Build partnerships with hospitals, clinics, and cardiologists who can endorse and recommend VivaHeart.AI to their patients.
- o Integrate VivaHeart.AI into Electronic Health Record (EHR) systems to simplify adoption for healthcare professionals.

#### 3. Regulatory Compliance:

- Ensure FDA/EMA approval is secured before launching in key markets, positioning the product as a trusted AI-powered diagnostic tool.
- o Compliance with GDPR and HIPAA will be crucial for ensuring patient data privacy and building trust with both users and providers.

#### 4. Education and Trust Building:

- o Develop educational content for users (e.g., Lucia) and healthcare providers to build trust in Al's ability to improve heart disease detection.
- o Provide Explainable AI features to make AI decisions transparent and understandable.

#### 5. Referral Programs and Incentives:

- o Offer referral incentives for early adopters to recommend VivaHeart.Al to friends and family, helping to drive organic growth.
- o Partner with insurance companies to offer VivaHeart.Al as part of preventive health packages, reducing healthcare costs associated with late-stage heart disease.

#### **Roll-Out Plan:**

## Phase 1: Pilot Launch (Months 1-3)

- **Geographic Focus:** Greece, Germany and Spain (regions with high female smoking rates).
- Target Users: Female smokers aged 40-60 and healthcare providers like cardiologists.

#### • Key Activities:

- Launch a closed pilot with a small group of users and healthcare providers to test functionality, gather feedback, and assess AI performance.
- o Monitor user experience, retention, and early diagnostic accuracy, adjusting the product as needed before a broader roll-out.

 Start building partnerships with key healthcare providers to drive user adoption in medical settings.

#### Phase 2: Soft Launch (Months 4-6)

- **Geographic Focus Expansion:** Broaden to additional European countries and parts of the U.S.
- Key Activities:
  - Expand access to more users and healthcare providers while refining features based on feedback from the pilot.
  - o Implement the **predictive health alert system**, providing real-time feedback to users based on wearable data and CT scans.
  - Launch targeted marketing campaigns aimed at female smokers and healthcare institutions.
  - Continue building regulatory approvals in other key regions, such as Canada and Australia.

#### Phase 3: Full Market Launch (Months 7-12)

- **Global Roll-Out:** Full-scale launch in key markets with high rates of female smoking (e.g., **France**, **Australia**, **Canada**).
- Key Activities:
  - Launch public marketing campaigns, including social media ads, partnerships with health organizations, and influencer marketing to build awareness.
  - Expand the real-time health monitoring feature and integrate more wearable devices for better user tracking and personalized insights.
  - **Refinement and scaling:** Continue to refine the AI model based on larger datasets, while scaling infrastructure to support more users.
  - Secure additional **healthcare partnerships** to integrate VivaHeart.AI into more hospitals and clinics globally.

#### **KPIs for Roll-Out:**

- **Pilot Phase:** Measure user engagement, AI model performance (accuracy, precision), and healthcare provider satisfaction.
- **Soft Launch:** Focus on user acquisition rates, referral program success, and feedback from healthcare professionals.
- **Full Launch:** Track global adoption rates, regulatory approvals, user retention, and improvements in health outcomes (e.g., smoking cessation, early detection rates).